09:19 AM EDT, 08/08/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Friday that a Type A meeting has been scheduled with the Food and Drug Administration to discuss the regulatory path for a biologics license application for its lead cell therapy Deramiocel.

To accommodate the meeting, Capricor said it has rescheduled the release of its Q2 financial results to Monday, Aug. 11, after the market close.

Capricor shares were up more than 1% in recent Friday premarket activity.